Gadolinium, a heavy metal used in MRI contrast agent dyes, may cause a serious illness – Gadolinium Deposition Disease – if it is retained in the body following a scan.
The nationwide law firm of Bernstein Liebhard LLP is offering free, no-obligation legal reviews to individuals who may be experiencing symptoms allegedly associated with Gadolinium Deposition Disease following an MRI. To discuss your case with one of our attorneys today, please call (888) 994-5118.
There are currently 8 gadolinium-based contrast agents approved for use in the United States:
These products have long been considered safe for patients with normal kidney function. However, several recent studies suggest that gadolinium deposits can remain in the brain and other parts of the body long after a patient has undergone an MRI.
Plaintiffs in a growing number of MRI contrast dye lawsuits claim that gadolinium toxicity from these deposits can result in a debilitating condition called Gadolinium Deposition Disease.
Symptoms of the disorder include at least 3 of the following:
Additional gadolinium side effects may include gastrointestinal issues, such as diarrhea and abdominal pain, as well as abnormal heart rhythms and other cardiac problems.
In December 2017, the FDA issued a class warning for gadolinium contrast dyes because of the risk that gadolinium could be retained in the brain or other parts of the body for weeks, months, and even years after a patient has undergone an MRI.
“To date, the only known adverse health effect related to gadolinium retention is a rare condition called nephrogenic systemic fibrosis (NSF) that occurs in a small subgroup of patients with pre-existing kidney failure,” the agency said. “We have also received reports of adverse events involving multiple organ systems in patients with normal kidney function. A causal association between these adverse events and gadolinium retention could not be established.”
While the warning applied to all 8 gadolinium-based MRI contrast dyes currently approved for sale in the United States, the FDA noted that certain products called linear agents — Eovist, Magnevist, Multihance, Omniscan, and OptimMARK — resulted in more retention and retention for a longer time compared to other agents.
The FDA is advising health care providers to consider the retention characteristics of each agent when choosing a gadolinium product for patients who may be at higher risk for retention, including:
You may be entitled to compensation for medical bills and other damages if you or someone you love developed symptoms of Gadolinium Deposition Disease following an MRI. To arrange for your free, no-obligation case review, please call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.